Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK.
Alzheimers Res Ther. 2010 Jan 22;2(1):1. doi: 10.1186/alzrt24.
Evidence for the involvement of inflammatory processes in the pathogenesis of Alzheimer's disease (AD) has been documented for a long time. However, the inflammation hypothesis in relation to AD pathology has emerged relatively recently. Even in this hypothesis, the inflammatory reaction is still considered to be a downstream effect of the accumulated proteins (amyloid beta (Abeta) and tau). This review aims to highlight the importance of the immune processes involved in AD pathogenesis based on the outcomes of the two major inflammation-relevant treatment strategies against AD developed and tested to date in animal studies and human clinical trials - the use of anti-inflammatory drugs and immunisation against Abeta.
很长一段时间以来，人们已经发现炎症过程参与了阿尔茨海默病（AD）的发病机制。然而，与 AD 病理学相关的炎症假说直到最近才出现。即使在这个假说中，炎症反应仍然被认为是积累的蛋白质（β淀粉样蛋白（Abeta）和 tau）的下游效应。本综述旨在根据迄今为止在动物研究和人类临床试验中针对 AD 开发和测试的两种主要与炎症相关的治疗策略的结果，强调参与 AD 发病机制的免疫过程的重要性——使用抗炎药物和针对 Abeta 的免疫接种。
